ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,070.55
1.20%
US Tech 100
17,078.00
1.94%
Dow Jones
38,503.69
0.69%
Brent Oil
87.565
1.34%
Bitcoin
66,389.33
-0.70%
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE

  6. Maxcyte Inc (MXCT) Quote

Maxcyte Inc

Maxcyte Inc (MXCT)

MaxCyte Inc
323.00
8.00
(2.54%)
Closed April 23 11:30AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
323.00
Bid
316.00
Ask
330.00
Volume
42,231
315.00 Day's Range 323.00
172.50 52 Week Range 420.00
Market Cap
392.282M
Previous Close
315.00
Open
315.00
Last Trade
570
@
321
(O)
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
26,132
Shares Outstanding
103,504,571
Dividend Yield
-
PE Ratio
-10.34
Earnings Per Share (EPS)
-0.37
Revenue
41.29M
Net Profit
-37.92M

About Maxcyte Inc

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.maxcyte.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Maxcyte Inc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker MXCT. The last closing price for Maxcyte was 315p. Over the last year, Maxcyte shares have traded in a share price range of 172.50p to 420.00p.

Maxcyte currently has 103,504,571 shares outstanding. The market capitalization of Maxcyte is £392.28 million. Maxcyte has a price to earnings ratio (PE ratio) of -10.34.

MXCT Latest News

More News

MaxCyte, Inc. Notice of Results

MaxCyte, Inc. 10 April 2024   MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024   ROCKVILLE, MD, April 10, 2024 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading...

April 10 2024
RNS Regulatory News

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

ROCKVILLE, Md., April 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...

April 10 2024
GlobeNewswire Inc.

MaxCyte, Inc. Total Voting Rights and Block Listing Return

MaxCyte, Inc. 03 April 2024   MaxCyte, Inc.   ("MaxCyte" or the "Company")   Total Voting Rights and Block Listing Return   ROCKVILLE, MD, April 3, 2024: MaxCyte, Inc., (Nasdaq: MXCT; LSE:...

April 03 2024
RNS Regulatory News

TRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian firms farmout

The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by A ...

April 02 2024
Alliance News

MaxCyte, Inc. Signing of Strategic Platform License

MaxCyte, Inc. 02 April 2024       MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)   Be Biopharma to use MaxCyte's...

April 02 2024
RNS Regulatory News

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...

April 02 2024
GlobeNewswire Inc.

MaxCyte, Inc. Exercise of options and PDMR dealing

MaxCyte, Inc. 02 April 2024     MaxCyte, Inc. ("MaxCyte" or the "Company")   Exercise of options and PDMR dealing   ROCKVILLE, MD, April 2, 2024: MaxCyte Inc., (Nasdaq: MXCT; LSE: MXCT), a...

April 02 2024
RNS Regulatory News

MaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR Dealing

MaxCyte, Inc. 20 March 2024     MaxCyte, Inc. ("MaxCyte" or the "Company")   Grant of Options, RSUs and PSUs and PDMR Dealing   Rockville, Maryland - 20 March 2024: MaxCyte Inc., (NASDAQ:...

March 20 2024
RNS Regulatory News

MaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR Dealing

MaxCyte, Inc. 20 March 2024     MaxCyte, Inc. ("MaxCyte" or the "Company")   Grant of Options, RSUs and PSUs and PDMR Dealing   Rockville, Maryland - 20 March 2024: MaxCyte Inc., (NASDAQ:...

March 20 2024
RNS Regulatory News

IN BRIEF: MaxCyte loss widens in 2023 as core revenue declines 25%

kville, Maryland-based provider of cell engineering platform technologies developing "next-generation cell therapeutic ...

March 13 2024
Alliance News
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
182.539682539683153233096379314.95416497DE
4-22-6.376811594234534530918628330.52336401DE
12-74.5-18.7421383648397.5400307.526132347.76675609DE
267831.836734693924542023537706359.36775853DE
52-87-21.2195121951410420172.530874335.4607681DE
156-512-61.31736526958351230172.566769672.22533668DE
260135.572.2666666667187.5123010588480555.72550068DE

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.23
(51.02%)
7.41M
TSLTT Rex 2X Long Tesla Daily Target ETF
$ 9.15
(24.32%)
2.8M
TSLRGraniteShares ETF Trust GraniteShares
$ 10.08
(24.29%)
307.29k
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 6.6901
(24.12%)
11.5M
ANNXAnnexon Inc
$ 5.11
(15.09%)
53.47k
TSDDGraniteShares ETF Trust GraniteShares
$ 26.85
(-24.37%)
222.14k
TSLZT Rex 2X Inverse Tesla Daily Target ETF
$ 42.30
(-24.36%)
847.68k
JYDJayud Global Logistics Ltd
$ 0.86
(-17.31%)
136.66k
TSLSGraniteShares ETF
$ 26.81
(-12.36%)
820.03k
TSLQAXS TSLA Bear Daily ETF
$ 40.43
(-12.22%)
797.29k
TSLATesla Inc
$ 162.58
(12.37%)
27.5M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 6.6901
(24.12%)
11.5M
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.23
(51.02%)
7.41M
SQQQProShares UltraPro Short QQQ
$ 11.75
(-1.34%)
5.72M
CYNCYNGN Inc
$ 0.1218
(6.84%)
5.21M

Discussion

View Full Feed
Golden Cross Golden Cross 18 seconds ago
I agree Herc, I wouldn't want to be short here...
AGBA
ChannelTrader ChannelTrader 24 seconds ago
FBI Codename For Trump Classified Documents Investigation Revealed

2 documents at the bottom of this post.

https://truthpress.com/news/fbi-codename-for-trump-classified-documents-investigation-revealed/

Judge Aileen Cannon on Monday ordered key evidence i
abracky abracky 2 minutes ago
https://www.clevelandcliffs.com/news/news-releases/detail/579/cleveland-cliffs-awarded-by-general-motors-gms-2022
CLF
Whalatane Whalatane 2 minutes ago
RE your view
Do you think Reduce It would even exist today if FDA had not mandated it? What would Amarin have to sell if they didnt?
You don't know that AMRN would never have run a CV outcome trial .

They may have on their own , for select subgroups like revascularisa
AMRN
cjstocksup cjstocksup 2 minutes ago
https://x.com/DC_Draino/status/1782876076730933539
scortech scortech 2 minutes ago
I could find any thing either.
Thanks Army
I do make sure when I'm driving I watch out for you guys
CGAC
toohot toohot 2 minutes ago
Thank you all. So much interest in my beloved BIEL.
‘Nuff said!




BUY $BIEL$
BIEL
vein vein 2 minutes ago
The chart is broken down
LWLG
Jronpar Jronpar 2 minutes ago
LikeRE's potential dynamic growth potential may shock and surprise many with the current problems facing NAR. My brother, a successful 40-year real estate broker, just sent me this informative video, "
This video pretty much explains where we are today regarding huge changes coming to the re
WDLF
snayeman snayeman 3 minutes ago
Do you have any info from anyone that possibly confirms your thoughts or are you just trying to connect dots? I know his silence suggests he’s checked out, which could mean he’s just screwed us over! Hopefully that’s not the case
IPIX
ZigZag1 ZigZag1 4 minutes ago
Bro, the fact that you didn’t agree with me tells me all I need to know about your “investing” knowledge. Tell me; what was it that got in this stock? The CEO? The business model? All the revenue? What was it?
FORW
Ecomike Ecomike 4 minutes ago
Indeed.
Mojocash Mojocash 4 minutes ago
Massive Move coming very soon.
YCRM
OMOLIVES OMOLIVES 5 minutes ago
Really dead stock movement considering the AFL starts this weekend. If it doesn't change within a few weeks...well...
AFL
trader59 trader59 5 minutes ago
They're into that 2nd 180 day period already. They need to hold the $1 for 6 more trading days.
SBFM
Saving Grace Saving Grace 5 minutes ago
To have a known basher stalking every single post I make and is a good indicator that I'm right on the money and getting under the punks skin. LoL SMH
SMH
LetGoodTimesRoll LetGoodTimesRoll 5 minutes ago
Perhaps the shorts will try that. However our CEO has majority control through Mr. Diamantis. If dividends are combined with share cancellations, the shorts will have to BEG for shares to cover.

$RNVA has a BRILLIANT CEO!!
RNVA
WebSlinger WebSlinger 6 minutes ago
>

That would take a TREMENDOUS amount of man-hours to accomplish. Imagine having a million cocoons in each room. And lets just say that you work 24 hou
KBLB
delerious1 delerious1 6 minutes ago
Peeps like you don't seem to understand what it takes to trade stocks....obviously you fell in and then out of love with the stock/CEO....your mistake not ours...get over it and move on
FORW
Mack101 Mack101 6 minutes ago
I meant 10 sec...
SPOM
abracky abracky 6 minutes ago
This will help CLF in the coming months.


General Motors (NYSE:GM) – Shares of GM rose 3.6% in pre-market trading after the company increased its projections for 2024 following a first-quarter performance that exceeded Wall Street expectations. GM revised its expected adjusted
CLF

Your Recent History

LSE
MXCT
Maxcyte
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved